Tudor Investment Corp’s Allogene Therapeutics ALLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-72,105
Closed -$176K – 3496
2026
Q1
$176K Buy
72,105
+1,097
+2% +$2.2K ﹤0.01% 3399
2025
Q4
$97.3K Hold
71,008
– – ﹤0.01% 3382
2025
Q3
$88K Hold
71,008
– – ﹤0.01% 3265
2025
Q2
$80.2K Hold
71,008
– – ﹤0.01% 3159
2025
Q1
$104K Buy
+71,008
New +$134K ﹤0.01% 2940
2024
Q3
– Sell
-71,340
Closed -$166K – 2665
2024
Q2
$166K Sell
71,340
-412
-0.6% -$1.22K ﹤0.01% 2176
2024
Q1
$321K Buy
+71,752
New +$299K ﹤0.01% 1827
2023
Q4
– Sell
-73,998
Closed -$235K – 2328
2023
Q3
$235K Buy
73,998
+63,135
+581% +$277K ﹤0.01% 2028
2023
Q2
$54K Buy
+10,863
New +$58.8K ﹤0.01% 2322
2023
Q1
– Sell
-77,228
Closed -$486K – 2361
2022
Q4
$486K Buy
77,228
+60,175
+353% +$557K 0.01% 1597
2022
Q3
$184K Buy
+17,053
New +$232K ﹤0.01% 2096
2022
Q2
– Sell
-171,247
Closed -$1.56M – 2067
2022
Q1
$1.56M Buy
171,247
+99,356
+138% +$1.03M 0.04% 672
2021
Q4
$1.07M Buy
+71,891
New +$1.27M 0.02% 954
2021
Q3
– Sell
-98,912
Closed -$2.58M – 2419
2021
Q2
$2.58M Buy
+98,912
New +$2.82M 0.05% 459
2021
Q1
– Sell
-12,120
Closed -$306K – 1534
2020
Q4
$306K Buy
12,120
+1,197
+11% +$39K 0.01% 1113
2020
Q3
$412K Sell
10,923
-39,476
-78% -$1.49M 0.02% 892
2020
Q2
$2.16M Buy
+50,399
New +$1.82M 0.11% 229

Other funds holding ALLO

Tudor Investment Corp's ALLO Position: Q2 2026 in Review

Tudor Investment Corp sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 72,105 shares — an estimated $176K sold.

Tudor Investment Corp first reported a position in ALLO in Q2 2020 and held it in 17 quarters. The position peaked at $2.58M in Q2 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Tudor Investment Corp reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Tudor Investment Corp sold 72,105 Allogene Therapeutics shares in Q2 2026, an estimated $176K.
  • Tudor Investment Corp first reported a position in Allogene Therapeutics in Q2 2020 and held it in 17 quarters.
  • Tudor Investment Corp's Allogene Therapeutics position peaked at $2.58M in Q2 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.